None listed
Conditions
Interventions
None listed
Sponsors
Daejeon Korean Medicine Hospital of Daejeon University
Kyung Hee University Oriental Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 19 years or older Individuals diagnosed with Parkinson’s disease according to the UK Parkinson’s Disease Society Brain Bank criteria Individuals who can be evaluated in the “ON” state after the effect of antiparkinsonian medication has appeared Individuals who voluntarily agree to participate in the study and provide written informed consent
Exclusion criteria
Exclusion criteria: 1) Individuals diagnosed with or suspected of having Parkinson-plus syndromes (e.g., multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, or dementia with Lewy bodies). 2) Individuals with neurologically or psychiatrically significant medical histories unrelated to Parkinson’s disease, or who currently suffer from other serious mental health disorders (e.g., major depressive disorder, bipolar disorder) that could affect assessment results. 3) Individuals diagnosed with dementia. 4) Individuals with a history of drug or alcohol abuse. 5) Individuals who have had acute severe cardiovascular diseases such as heart failure, myocardial infarction, or stroke, or malignant tumors within six months prior to the date of consent. 6) Individuals deemed unsuitable for participation in the study by the principal investigator for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pattern identification questionnaire ;MDS-Unified Parkinson’s Disease Rating Scale (UPDRS) I, II, III;Scale for Outcomes in Parkinson’s disease for Autonomic Symptoms (SCOPA-AUT) ;Montreal Cognitive Assessment (MoCA) | — |
Secondary
| Measure | Time frame |
|---|---|
| blood transcriptome analysis | — |
Countries
Korea, Republic of
Contacts
Public ContactJunyoung Hur
Daejeon Korean Medicine Hospital of Daejeon University
Outcome results
None listed